Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension.

Paola Di BenedettoGiuliana GugginoGiovanna ManziPiero RuscittiOnorina BerardicurtiNoemi PanzeraNicolò GraziaRoberto BadagliaccaValeria RiccieriCarmine Dario VizzaGanna RadchenkoVasiliki LiakouliFrancesco CicciaPaola CiprianiRoberto Giacomelli

Published in: Arthritis research & therapy (2020)

Our study suggested that sera determination of IL-32 may be a promising approach to evaluate the presence of PAH in SSc patients and together with longitudinal future studies could help to increase the understanding how these biomarkers mirror the vascular changes and the inflammatory process during SSc.

Keyphrases

systemic sclerosis
pulmonary arterial hypertension
interstitial lung disease
pulmonary hypertension
pulmonary artery
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
cross sectional
rheumatoid arthritis
current status
coronary artery
high resolution
risk assessment